Vizgen launches integrated Merscope in situ imaging platform

By The Science Advisory Board staff writers

March 1, 2021 -- Vizgen has launched its Merscope platform, a multiplexed, error-robust, single-cell in situ transcriptomic imaging technology.

Merscope is an integrated solution that combines single-cell and spatial genomics analysis. The system provides a streamlined workflow from sample preparation through data visualization for in situ analysis in fundamental biology and medicine applications.

Vizgen
Vizgen's Merscope is the first commercial solution to combine single-cell and spatial genomics analysis for advancing cellular and molecular biology research. Image courtesy of Vizgen.

Merscope is based on multiplexed error-robust fluorescence in situ hybridization (MERFISH) technology developed by Xiaowei Zhuang, PhD, a Howard Hughes Medical Institute investigator. Merscope provides combinatorial labeling, sequential imaging, and error-robust barcoding to provide nanometer-scale resolution across whole tissues, according to the company. The imaging-based approach enables hundreds of genes to be profiled within hundreds of thousands of cells in a single instrument run without the need for expensive sequencing.

Vizgen's commercially available equipment is designed for flexibility on any sample or tissue type and includes validated or custom gene panels, reagents, and consumables; fully automated instrumentation; and data visualization software.

The company will present the technology on March 2 at the Advances in Genome Biology and Technology (AGBT) 2021 General Meeting.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.